Marcaine


Also found in: Dictionary.

bupivacaine

A potent long-acting amide-class local anaesthetic with a 4–8 hour duration of action, which is doubled by adding adrenaline/epinephrine.

Adverse effects
• CNS toxicity—Nervousness, perioral tingling, tinnitus, tremor, dizziness, blurred vision and seizures, followed by drowsiness, loss of consciousness, respiratory depression and apnoea.
• Cardiotoxicity—Hypotension, bradycardia, arrhythmias and cardiac arrest.

Marcaine®

Bupivacaine, see there.

Marcaine

The long-acting local anaesthetic drug BUPIVACAINE. The effect lasts for about 4 hours.

Marcaine,

n a trade name for bupivacaine, a long-acting local anesthetic agent.
References in periodicals archive ?
After injection of 15mg (3 ml) heavy Marcaine into the subarachnoid space, 3cm of epidural catheter was placed into epidural space.
Portals were closed and marcaine with epinephrine injected into the portals and joint.
Marcaine will have a stronger effect than lidocaine.
Table 1: Common local and regional anaesthetic agents (Taken from Phillips 2007 page 447) Generic name Trade name Uses Concentration Duration of effect (hours) Bupivacaine Marcaine Local 0.
Treatment groups included: group 1) bupivacaine, 2 mg/kg (5 mg/mL perineural; Marcaine, Astra Zeneca, Wilmington, DE, USA); group 2) bupivacaine, 8 mg/kg; group 3) lidocaine, 15 mg/kg (20 mg/mL perineural) combined with epinephrine, 3.
5 Marcaine Epinephrine 3M ESPE 4 Espetesin Epinephrine 4 Espetesin Epinephrine Company % Amount mL Dentsply 2 1.
Pain pumps are designed and intended for commonly used anesthetics such as lidocaine or marcaine, with or without epinephrine.
30) Fitzgerald reported that 7 out of 55 patients experienced complete symptom relief after injection of marcaine and celestone, and partial weightbearing on crutches for 4 weeks.
He tried common analgesics, Novocaine, Xylocaine, Marcaine, steroids and cortisone and was addicted for 13 years to hard-core painkiller Percodan.
18 September 2017 - UK-based drugmaker AstraZeneca (NYSE: AZN) has entered into an agreement with Mauritius-based Aspen Group's Aspen Global Inc business under which AGI will now acquire the residual rights to the established anaesthetic medicines comprising of Diprivan, EMLA,Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest, the company said.
The portfolio contains brands like Carbocaine, Citanest, Diprivan, Marcaine and Naropin, and it continues to generate stable revenue, with global product sales in 2015 of US$ 592mln.
25% Marcaine with epinephrine in the umbilicus for preemptive analgesia.